Last reviewed · How we verify
HyperAcute vaccine
The HyperAcute vaccine works by stimulating the body's immune system to recognize and fight specific diseases.
The HyperAcute vaccine works by stimulating the body's immune system to recognize and fight specific diseases. Used for COVID-19 prevention.
At a glance
| Generic name | HyperAcute vaccine |
|---|---|
| Sponsor | Ochsner Health System |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This vaccine uses a weakened or inactivated form of a disease-causing agent to trigger an immune response, which can provide long-term protection against future infections.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer (PHASE1)
- Vaccine Treatment for Hormone Refractory Prostate Cancer (PHASE1, PHASE2)
- Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer (PHASE2)
- Vaccine Study for Surgically Resected Pancreatic Cancer (PHASE2)
- Vaccine Treatment for Surgically Resected Pancreatic Cancer (PHASE1, PHASE2)
- Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer (PHASE2, PHASE3)
- Vaccine Treatment for Advanced Breast Cancer (PHASE1, PHASE2)
- Vaccine Treatment for Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HyperAcute vaccine CI brief — competitive landscape report
- HyperAcute vaccine updates RSS · CI watch RSS
- Ochsner Health System portfolio CI